About Chi-Fu Jeffrey Yang, MD

Dr. Chi-Fu Jeffrey Yang is a thoracic surgeon at Massachusetts General Hospital and an Assistant Professor of Surgery at Harvard Medical School.  He received his bachelor's degree in biochemistry from Harvard College and his medical degree at Harvard Medical School. He completed his general surgery residency at Duke University and cardiothoracic surgery fellowship at Stanford University Medical Center. 

Dr. Yang practices all aspects of thoracic surgery, including procedures for benign and malignant conditions of the lung, esophagus, mediastinum and chest wall. He specializes in minimally invasive techniques, including using VATS and robotic approaches.  Dr. Yang has received numerous awards, including recognition for exceptional accomplishment in both clinical care and in teaching.  In 2021, he received the Harvard Medical School Charles McCabe Faculty Prize for Excellence in Teaching.

Dr. Yang’s research focus is in the field of thoracic oncology and he performs clinical research.  He is the recipient of the 2021 AATS Foundation Surgical Investigator Award. Dr. Yang has been the lead or senior author on several high impact papers published in the Journal of Clinical Oncology, Lancet Respiratory Medicine, Journal of Thoracic Oncology, Annals of Surgery, and Chest.  He has written over 100 publications, including over 60 as first-, co-first or senior author. Dr. Yang is an editorial board member of the Journal of Thoracic and Cardiovascular Surgery, the Journal of Thoracic Diseases, and the Society of Thoracic Surgeons Online Curriculum.

Dr. Yang is also focused on raising awareness of lung cancer screening. He started the American Lung Cancer Screening Initiative, a 501(c)(3) non-profit, which has worked with communities across 50 states to highlight the importance of lung cancer screening. In 2020 and 2021, he co-drafted resolutions, S. Res. 780 and S. Res. 426, to raise awareness for lung cancer and lung cancer screening that passed in the U.S. Senate, by unanimous support from all 100 U.S. Senators. In 2021, he received the Harvard Medical School Dean's Community Service Faculty Award in recognition of his efforts.

When Dr. Yang is not at Mass General, he enjoys spending time with his wife, Phoebe, two daughters and his dog.

Departments, Centers, & Programs:

Clinical Interests:



Mass General Surgery: Thoracic Surgery
55 Fruit St.
Boston, MA 02114
Phone: 617-726-2100

Wentworth-Douglass Hospital
789 Central Ave.
Dover, NH 03820
Phone: 603-742-5252

Medical Education

  • MD, Harvard Medical School
  • Residency, Duke University Medical Center
  • Fellowship, Stanford University Hospital

American Board Certifications

  • Surgery, General, American Board of Surgery
  • Thoracic and Cardiac Surgery - General, American Board of Thoracic Surgery

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • Mayne NR, Elser H, Darling AJ, Raman V, Liou D, Colson YL, D’Amico TA, Yang CJ. Estimating the Impact of Extended Delay to Surgery for Stage I Non-Small-Cell Lung Cancer on Survival. Annals of Surgery 2021. 273(5): 850-857. 

    Mayne NR, Lin BK, Darling AJ, Raman V, Patel D, Liou D, D’Amico TA, Yang CJ.  Stereotactic Body Radiotherapy versus Delayed Surgery for Early Stage Non-small-cell Lung Cancer.  Annals of Surgery 2020. 272(6):925-929. 

    Yang CJ et al.  A National Analysis of Long-term Survival Following Thoracoscopic versus Open Lobectomy for Stage I Non-small-cell Lung Cancer.  Annals of Surgery 2019. 269 (1):163-171. 

    Yang CJ et al. A National Analysis of Short-term Outcomes and Long-term Survival Following Thoracoscopic vs Open Lobectomy for Clinical Stage II Non-small-cell Lung Cancer. Annals of Surgery 2019. 273(3):595-605.  

    Yang CJ et al. Long-term Survival After Surgery Compared with Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer.  Annals of Surgery 2018. 268(6):1105-1112. 

    Yang CJ et al. Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma. Chest 2017. 152(6):1239-1250. 

    Yang CJ et al. Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology 2016, 34(10):1057-64. 

Reviews: Comments and Ratings